On Thursday, Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)’s shares declined -7.41% to $1.00.
Lexicon Pharmaceuticals, Inc. (LXRX) declared that it will effect a reverse stock split at a ratio of one share of newly issued common stock for each seven shares of issued and outstanding common stock. Lexicon anticipates that the reverse stock split will be effective at 5:00 p.m. Eastern Time on May 20, 2015, and that its common stock will commence trading on a split-adjusted basis as of the opening of trading on May 21, 2015.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of human diseases. Its drug development programs comprise telotristat etiprate, an orally-delivered small molecule drug candidate, which is in Phase III clinical trials for the treatment of carcinoid syndrome.
Accuray Incorporated (NASDAQ:ARAY)’s shares dropped -7.40% to $8.13.
Accuray Incorporated (ARAY) declared that it has signed a contract with MIM Software Inc. to further develop adaptive therapy software for the TomoTherapy® and CyberKnife® product portfolios. The new software solution will leverage both Accuray and MIM technology. This is Accuray’s second partnershipwith MIM; the previous partnership led to the development of the first iPad-based treatment plan review capability, PlanTouch™.
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. Its CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, in addition to enables delivery of precise, high dose radiation while patients breathe normally.
At the end of Thursday’s trade, Depomed Inc (NASDAQ:DEPO)‘s shares dipped -7.07% to $23.26.
Depomed Inc (DEPO) declared that it will release first quarter fiscal year 2015 financial results after the market closes on Monday, May 11, 2015. The Company will host a conference call startning at 4:30 pm EDT, 1:30 pm PDT to talk about its results
Depomed, Inc., a specialty pharmaceutical company, develops products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the administration of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults; and Lazanda (fentanyl) nasal spray, an intranasal fentanyl drug used to manage breakthrough pain in adults.
Agios Pharmaceuticals Inc (NASDAQ:AGIO), ended its Thursday’s trading session with -7.03% loss, and closed at $92.34.
Agios Pharmaceuticals Inc (AGIO) declared that the company will host a conference call and live webcast on Thursday, May 7, 2015 at 8:30 a.m. EDT to report its first quarter 2015 financial results and talk about recent clinical development and corporate activities.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism in the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
